Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition

ARB/NEP 抑制引起低血压反应的机制

基本信息

  • 批准号:
    10186795
  • 负责人:
  • 金额:
    $ 71.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-15 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Twenty percent of people in the United States will develop heart failure during their lives. Despite beneficial effects of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor antagonists on mortality, the five-year life expectancy of a patient with heart failure is fifty percent. In 2015, the FDA approved LCZ696 (Entresto™), a molecular complex of the ARB valsartan and sacubitril, a neprilysin (neutral endopeptidase-24.11) inhibitor prodrug, after LCZ696 reduced mortality compared to enalapril in a randomized clinical trial in patients with heart failure, reduced ejection fraction, and increased circulating brain natriuretic peptide (BNP) or N-terminal (NT) proBNP. LCZ696 also reduces rehospitalization in acutely decompensated heart failure. Nevertheless, LCZ696 has been underutilized in clinical practice, and concerns regarding hypotension have impeded use. The mechanism(s) through which the combined ARB and neprilysin inhibitor reduces blood pressure are not fully known. Neprilysin degrades many vasoactive peptides including the natriuretic peptides, angiotensins (Ang) I and II, endothelins, bradykinin, and substance P. In heart failure patients, LCZ696 increases BNP, a neprilysin substrate, while decreasing the non-neprilysin substrate NT-proBNP, suggesting that LCZ696 potentiates effects of the natriuretic peptide. On the other hand, natriuretic peptides are poor substrates for neprilysin compared to bradykinin and substance P, which can have beneficial effects on blood pressure, diuresis, natriuresis, fibrinolysis and remodeling but also contribute to adverse effects like hypotension and angioedema. Our research group has extensive experience studying the contribution of peptides to drugs that inhibit vasopeptidases such as ACE, dipeptidyl peptidase-4 (DPP4), and neprilysin. In this proposal, we test the overarching hypothesis that bradykinin contributes to vasodilator, blood pressure and renal effects of combined angiotensin receptor blockade/neprilysin inhibition. In Aim 1, we will test the hypothesis that LCZ696 potentiates the effects of intra-arterial bradykinin, substance P, or BNP compared to valsartan alone. We will test this hypothesis in the presence and absence of a DPP4 inhibitor, as it may enhance effects of neprilysin inhibition. In Aim 2, we will test the hypothesis that endogenous bradykinin contributes to hypotensive, natriuretic and diuretic effects of LCZ696 during initiation and up-titration in heart failure patients using a bradykinin B2 receptor antagonist. In Aim 3, we will probe the contribution of endogenous substance P to effects of LCZ696 using a substance P (NK1) receptor antagonist. In the combined Aims 2 and 3, we will assess individual patient factors such as race, gender, BNP (measured both by clinical immunoassay and by specific mass spectrometric assay), and NEP activity that predict blood pressure response to LCZ696. These studies will provide novel information about the mechanism(s) of action of combined angiotensin receptor blockade and neprilysin inhibition, and lead to new strategies to minimize adverse effects while maximizing beneficial effects of this promising new class of drugs for heart failure.
项目总结 美国有20%的人会在一生中患上心力衰竭。尽管有益 血管紧张素转换酶(ACE)抑制剂、血管紧张素受体阻滞剂(ARB)、β受体阻滞剂、 和盐皮质激素受体拮抗剂对心力衰竭患者死亡率、预期寿命的影响 是50%。2015年,FDA批准了Arb valsartan和Arb valsartan的分子络合物LCZ696(Entresto™)。 舒必利,一种奈普利辛(中性内肽酶-24.11)抑制剂前药,LCZ696后降低死亡率的比较 依那普利在心力衰竭患者的随机临床试验中,降低了射血分数,增加了 循环脑利钠肽(BNP)或N末端(NT)proBNP。LCZ696还减少了 严重失代偿性心力衰竭。然而,LCZ696在临床实践中一直没有得到充分利用,而且 对低血压的担忧阻碍了它的使用。ARB和ARB结合的机制(S) 奈普利辛抑制剂降低血压的作用尚不完全清楚。奈普利辛可降解多种血管活性多肽 包括利钠肽、血管紧张素(Ang)I和II、内皮素、缓激肽和P物质。 衰竭患者,LCZ696增加脑钠素底物,同时减少非脑纤溶素底物 NT-proBNP,提示LCZ696增强了利钠肽的作用。另一方面,利钠药 与缓激肽和P物质相比,多肽是neprilysin的较差底物,这可能有好处 对血压、利尿、利钠、纤溶和重塑的影响,但也会造成不良影响 比如低血压和血管水肿。我们的研究小组有丰富的经验研究 抑制血管肽酶的药物,如血管紧张素转换酶、二肽基肽酶-4(DPP4)和奈普利辛。在这 提案中,我们检验了缓激肽对血管扩张剂、血压和肾脏有贡献这一重要假设。 血管紧张素受体拮抗剂/奈普利辛联合应用的效果。在目标1中,我们将检验假设 与单独使用valsartan相比,LCZ696可增强动脉内注射缓激肽、P物质或BNP的作用。 我们将在存在和不存在DPP4抑制剂的情况下检验这一假设,因为它可能会增强 Neprilysin抑制。在目标2中,我们将检验内源性缓激肽有助于降压的假设, LCZ696在心力衰竭患者起效和上滴定过程中的利钠利尿作用 缓激肽B2受体拮抗剂。在目标3中,我们将探讨内源性P物质对效应的贡献 使用P物质(NK1)受体拮抗剂。在综合目标2和目标3中,我们将评估 个别患者的因素,如种族、性别、BNP(通过临床免疫分析和特定的 质谱分析)和NEP活性预测对LCZ696的血压反应。这些研究 将为血管紧张素受体拮抗剂联合应用的作用机制(S)提供新的信息。 抑制Neprilysin,并导致新的策略,以最大限度地减少不利影响,同时最大化有益的影响 这一前景看好的治疗心力衰竭的新药。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nancy J. Brown其他文献

Les effets secondaires aigus des inhibiteurs de l’enzyme de conversion de l’angiotensine dont l’angioœdème, différents dans leur étiologie clinique, partagent une physiopathologie semblable
血管紧张素转化酶抑制剂的第二效应与血管紧张素转化酶的效果不同,与临床病因学不同,与病理生理学相似
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. Désormeaux;James Brian Byrd;Nancy J. Brown;A. Adam
  • 通讯作者:
    A. Adam
Coordinated responses of plasma 20-HETE and soluble epoxide hydrolase to salt in normal subjects: alterations in salt-sensitive normotension
  • DOI:
    10.1016/j.jash.2014.03.254
  • 发表时间:
    2014-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Fernando Elijovich;Nancy J. Brown;Ginger L. Milne;Cheryl L. Laffer
  • 通讯作者:
    Cheryl L. Laffer
Abstracts from the 10th C1-inhibitor deficiency workshop
  • DOI:
    10.1186/s13223-017-0198-5
  • 发表时间:
    2017-06-15
  • 期刊:
  • 影响因子:
    2.400
  • 作者:
    Alvin H. Schmaier;Marco Cicardi;Avner Reshef;Dumitru Moldovan;Attila Mócsai;Margarita López-Trascasa;Alberto López Lera;Nancy J. Brown;Anastasios E. Germenis;Rafael Filippelli-Silva;Diego A. Duarte;Renan P. Martin;Camila L. Veronez;Michel Bouvier;Michael Bader;Claudio M. Costa-Neto;João Bosco Pesquero;Xavier Charest-Morin;François Marceau;Georges-É. Rivard;Arnaud Bonnefoy;Éric Wagner;Márta L. Debreczeni;Zsuzsanna Németh;Erika Kajdácsi;Endre Schwaner;László Cervenak;Gábor Oroszlán;András Szilágyi;Ráhel Dani;Péter Závodszky;Péter Gál;József Dobó;Jacques Hébert;Matthieu Vincent;Jean-Nicolas Boursiquot;Hugo Chapdeleine;Marylin Desjardins;Benoit Laramée;Rémi Gagnon;Nancy Payette;Oleksandra Lepeshkina;Delphine Charignon;Arije Ghannam;Denise Ponard;Christian Drouet;Kusumam Joseph;Baby G. Tholanikunnel;Daniel J. Sexton;Allen P. Kaplan;Stefania Loffredo;Maria Bova;Anne Lise Ferrara;Angelica Petraroli;Chiara Suffritti;Nóra Veszeli;Andrea Zanichelli;Henriette Farkas;Gianni Marone;Samuel Luyasu;Bertrand Favier;Ludovic Martin;Kinga Viktória Kőhalmi;György Temesszentandrási;Katalin Várnai;Lilian Varga;Bruce L. Zuraw;Annette Feussner;Michael A. Tortorici;Dipti Pawaskar;Huamin Henry Li;John Anderson;Jonathan A. Bernstein;Ying Zhang;Ingo Pragst;Emel Aygören-Pürsün;Kraig Jacobson;Jim Christensen;Arthur Van Leerberghe;Yi Wang;Jennifer Schranz;Inmaculada Martinez-Saguer;Daniel Soteres;Urs Steiner;Vesna Grivcheva Panovska;William Rae;Werner Aberer;Aarnoud Huissoon;Anette Bygum;Markus Magerl;Jochen Graff;Hilary Longhurst;Ramón Lleonart;Lei Fang;Melanie Cornpropst;Desiree Clemons;Amanda Mathis;Phil Collis;Sylvia Dobo;William P. Sheridan;Marcus Maurer;Marc A. Riedl;Timothy Craig;Aleena Banerji;Mustafa Shennak;William Yang;Jovanna Baptista;Paula Busse;Ira Kalfus;Andrew McDonald;Shawn Qian;Anthony Roberts;Con Panousis;Tim Green;Andreas Gille;Maria Zamanakou;Gedeon Loules;Dorottya Csuka;Fotis Psarros;Faidra Parsopoulou;Matthaios Speletas;Davide Firinu;Tiziana Maria Angela De Pasquale;Alessandra Zoli;Anna Radice;Stefano Pizzimenti;Emmanouil Manoussakis;George N. Konstantinou;Valeria Bafunno;Vincenzo Montinaro;Mauro Cancian;Maurizio Margaglione;Konrad Bork;Karin Wulff;Guenther Witzke;Jochen Hardt;Laurence Bouillet;Teresa Caballero;Anete S. Grumach;Christelle Pommie;Irmgard Andresen;Carmen Escuriola Ettingshausen;Zeynep Gutowski;Karin Andritschke;Richard Linde;Noémi Andrási;Tamás Szilágyi;Iris Leibovich-Nassi;Christine Symons;John Dempster;Isabelle Boccon-Gibod;Anne Pagnier;Audrey Lehmann;Kristian B. Kreiberg;Sandra A. Nieto;Raquel Martins;Renata Martins;Alejandra Menendez;Solange O. R. Valle;Margarita Olivares;Maria E. Hernandez-Landeros;Elma Nievas;Natalia Fili;Olga M. Barrera;René Bailleau;Ana Maria Gallardo-Olivos;Masumi Grau;Julian Rodriguez-Galindo;Marlon J. O. Carabantes;Edison Zapata-Venegas;Mario Martinez Alfonso;Maria Rosario-Grauert;Manuel Ratti;Daniel Vaszquez;Dario Josviack;Luis Fernando Landivar-Salinas;Oscar M. E. Calderón-Llosa;Rolando Campilay-Sarmiento;Pablo Raby;Jose Fabiani;William R. Lumry;Henrike Feuersenger;Douglas J. Watson;Thomas Machnig;Donatella Lamacchia;Adriana Hernanz;Ana Alvez;Mariana Lluncor;Maria Pedrosa;Rosario Cabañas;Nieves Prior;Patrik Nordenfelt;Mats Nilsson;Anders Lindfors;Carl-Fredrik Wahlgren;Janne Björkander;Roman Hakl;Pavel Kuklínek;Irena Krčmová;Jana Hanzlíková;Martina Vachová;Radana Zachová;Marta Sobotková;Jana Strenková;Jiří Litzman;Maria Palasopoulou;Gerasimina Tsinti;Panagiota Gianni;Maria Kompoti;Sofia Garrido;Wojciech Dyga;Anna Bogdali;Aleksander Obtułowicz;Mikolajczyk Tomasz;Ewa Czarnobilska;Krystyna Obtulowicz;Teofila Książek;Anna Koncz;Dominik Gulyás;Maria Staevska;Milos Jesenak;Katarina Hrubiskova;L. Bellizzi;A. Relan;Maddalena A. Wu;Antonio Castelli;Riccardo Colombo;Gianmarco Podda;Marta Del Medico;Emanuele Catena;Francesco Casella;Francesca Perego;Nada Afifi Afifi;Eleonora Tobaldini;Nicola Montano;Marta Sánchez-Jareño;Marcin Stobiecki;Krystyna Obtułowicz;Irina Guryanova;Ekaterina Polyakova;Viktar Lebedz;Andrej Salivonchik;Svetlana Aleshkevich;Mikhail Belevtsev;Melanie Nordmann-Kleiner;Susanne Trainotti;Janina Hahn;Jens Greve;Liudmyla Zabrodska;Maria L. Oliva Alonso;Rosangela P. Tórtora;Alfeu T. França;Marcia G. Ribeiro;Lisa Fu;Amin Kanani;Gina Lacuesta;Susan Waserman;Stephen Betschel;Melissa I. Espinosa;Francisco A. Contreras;Martin Hrubisko;Ludmila Vavrova;Peter Banovcin;Maryam Ayazi;Mohammad Reza Fazlollahi;Shiva Saghafi;Sajedeh Mohammadian;Susan Nabilou Deshiry;Kiana Bidad;Raheleh Shokouhi Shoormasti;Iraj Mohammadzadeh;Mohammad Hassan Bemanian;Seyed Alireza Mahdaviani;Zahra Pourpak;Anna Valerieva;Mariela Vasileva;Tsvetelina Velikova;Elena Petkova;Vasil Dimitrov;Ruggero Di Maulo;Raz Somech;Hava Golander;Erika J. Sifuentes;Catherine Mansard;Anne Gompel;Bernard Floccard;Claire Blanchard-Delaunay;David Launay;Olivier Fain;Alain Sobel;Stéphane Gayet;Stéphanie Amarger;Guillaume Armengol;Yann Ollivier;Ariane Zélinsky-Gurung;Pierre-Yves Jeandel;Gisèle Kanny;Brigitte Coppéré;Marie Dubrel;Fabien Pelletier;Aurélie Du Thanh;Sébastien Trouiller;Jérôme Laurent;Claire De Moreuil;Christine Audouin Pajot;Alexandre Belot;Ana Rodríguez;Dasha Roa;Alicia Prieto;Maria Luisa Baeza;Borislava Krusheva;Stephanie K. A. Almeida;Rosemeire N. Constantino-Silva;Nyla Melo;Joanna Araujo Simoes;Sandra Mitie U. Palma;Jane da Silva;Bruna F. de Azevedo;Eli Mansour;Teresa González-Quevedo;Carmen Marcos;Teófilo Lobera;Blanca Sáenz de San Pedro;Ernie Avilla;Jacquie Badiou;Karen Binkley;Rozita Borici-Mazi;Linda Howlett;Paul K. Keith;Anne Rowe;Peter Waite;Aurore Billebeau;Isabelle Boccon-Gibbod;Kristina Lis;Yael Laitman;Eitan Friedman;N. M. Gokmen;O. Gulbahar;H. Onay;Z. P. Koc;A. Z. Sin
  • 通讯作者:
    A. Z. Sin

Nancy J. Brown的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nancy J. Brown', 18)}}的其他基金

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
ARB/NEP 抑制引起低血压反应的机制
  • 批准号:
    9884685
  • 财政年份:
    2020
  • 资助金额:
    $ 71.09万
  • 项目类别:
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
ARB/NEP 抑制引起低血压反应的机制
  • 批准号:
    10456298
  • 财政年份:
    2020
  • 资助金额:
    $ 71.09万
  • 项目类别:
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
ARB/NEP 抑制引起低血压反应的机制
  • 批准号:
    10755424
  • 财政年份:
    2020
  • 资助金额:
    $ 71.09万
  • 项目类别:
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
ARB/NEP 抑制引起低血压反应的机制
  • 批准号:
    10620715
  • 财政年份:
    2020
  • 资助金额:
    $ 71.09万
  • 项目类别:
Variation in Soluble Epoxide Hydrolase Activity and Human Insulin Sensitivity
可溶性环氧化物水解酶活性和人胰岛素敏感性的变化
  • 批准号:
    10170332
  • 财政年份:
    2018
  • 资助金额:
    $ 71.09万
  • 项目类别:
Variation in Soluble Epoxide Hydrolase Activity and Human Insulin Sensitivity
可溶性环氧化物水解酶活性和人胰岛素敏感性的变化
  • 批准号:
    9981733
  • 财政年份:
    2018
  • 资助金额:
    $ 71.09万
  • 项目类别:
Cardiovascular Consequences of Peptidase Inhibition
肽酶抑制的心血管后果
  • 批准号:
    9257457
  • 财政年份:
    2015
  • 资助金额:
    $ 71.09万
  • 项目类别:
Cardiovascular Consequences of Peptidase Inhibition
肽酶抑制的心血管后果
  • 批准号:
    9270750
  • 财政年份:
    2015
  • 资助金额:
    $ 71.09万
  • 项目类别:
Cardiovascular Consequences of Peptidase Inhibition
肽酶抑制的心血管后果
  • 批准号:
    8960866
  • 财政年份:
    2015
  • 资助金额:
    $ 71.09万
  • 项目类别:
Recombinant Neuregulin for the treatment of Heart Failure
重组神经调节蛋白治疗心力衰竭
  • 批准号:
    7867106
  • 财政年份:
    2010
  • 资助金额:
    $ 71.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了